The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance

Investigative Radiology

Volumn 46, Issue 12, 2011, Pages 807-816

  Runge, Val M ^a   Ai, Tao ^b   Hao, Dapeng ^c   Hu, Xuemei ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

gadolinium; intravenous contrast media; magnetic resonance (MR)

Indexed keywords

ECHOVIST; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM CHELATE; GADOLINIUM EDETATE; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID;

DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; THERMOSTABILITY; TISSUE PERFUSION;

EID: 81855220356     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318237913b     Document Type: Review

References (162)

1. Runge VM, Stewart RG, Clanton JA, et al. Paramagnetic NMR contrast agents: potential oral and intravenous agents. Oral presentation at: Radiological Society of North America annual meeting, November, 1982; Chicago, IL.
2. Runge VM. Enhanced Magnetic Resonance Imaging. St. Louis, MO: C.V. Mosby Company; 1989.
3. Runge VM, Stewart RG, Clanton JA, et al. Work in progress: potential oral and intravenous paramagnetic NMR contrast agents. Radiology. 1983;147: 789-791. (Pubitemid 13090114)
4. Runge VM, Clanton JA, Foster MA, et al. Paramagnetic NMR contrast agents. Development and evaluation. Invest Radiol. 1984;19:408-415. (Pubitemid 14010091)
5. Runge VM, Clanton JA, Lukehart CM, et al. Paramagnetic agents for contrast-enhanced NMR imaging: a review. Am J Roentgenol. 1983;141: 1209-1215. (Pubitemid 14210850)
6. Runge VM, Clanton JA, Price AC, et al. Paramagnetic contrast agents in magnetic resonance imaging: research at Vanderbilt University. Physiol Chem Phys Med NMR. 1984;16:113-122.
7. Runge VM, Clanton JA, Herzer WA, et al. Intravascular contrast agents suitable for magnetic resonance imaging. Radiology. 1984;153:171-176. (Pubitemid 14043403)
8. Enzmann DR, Britt RH, Yeager AS. Experimental brain abscess evolution: computed tomographic and neuropathologic correlation. Radiology. 1979; 133:113-122. (Pubitemid 9249529)
9. Runge VM, Clanton JA, Price AC, et al. Dyke Award. Evaluation of contrast-enhanced MR imaging in a brain-abscess model. Am J Neuroradiol. 1985;6:139-147. (Pubitemid 15144950)
10. Runge VM, Price AC, Wehr CJ, et al. Contrast enhanced MRI. Evaluation of a canine model of osmotic blood-brain barrier disruption. Invest Radiol. 1985;20:830-844. (Pubitemid 16234408)
11. Runge VM, Clanton JA, Price AC, et al. The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption. Magn Reson Imaging. 1985;3:43-55. (Pubitemid 15075062)
12. Carr DH, Brown J, Bydder GM, et al. Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. Am J Roentgenol. 1984; 143:215-224. (Pubitemid 14051280)
13. Laniado M, Weinmann HJ, Schorner W, et al. First use of GdDTPA/dimeglumine in man. Physiol Chem Phys Med. 1984;16:157-165.
14. Runge VM, Schoerner W, Niendorf HP, et al. Initial clinical evaluation of gadolinium DTPA for contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 1985;3:27-35. (Pubitemid 15075060)
15. Runge VM, Jacobson S, Wood ML, et al. MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA. Radiology. 1988;166:835-838. (Pubitemid 18058952)
16. Runge VM, Kaufman DM, Wood ML, et al. Experimental trials with Gd(DO3A)-a nonionic magnetic resonance contrast agent. Int J Rad Appl Instrum B. 1989;16:561-567. (Pubitemid 19237455)
17. Runge VM, Kirsch JE, Thomas GS. High-dose applications of gadolinium chelates in magnetic resonance imaging. Magn Reson Med. 1991;22:358-363.
18. Runge VM, Kirsch JE, Burke VJ, et al. High-dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging. 1992;2:9-18.
19. Runge VM, Kirsch JE, Wells JW, et al. Magnetic resonance contrast agents in neuroimaging. New agents and applications. Neuroimaging Clin N Am. 1994;4:175-183. (Pubitemid 24074764)
20. Runge VM, Kirsch JE, Wells JW, et al. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material. Am J Roentgenol. 1994;162: 431-435. (Pubitemid 24065449)
21. Runge VM, Wells JW, Nelson KL, et al. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol. J Magn Reson Imaging. 1994;4:669-673.
22. Runge VM, Wells JW, Williams NM. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability. Invest Radiol. 1994;29:1050-1056.
23. Runge VM, Wells JW, Kirsch JE. Magnetization transfer and high-dose contrast in early brain infection on magnetic resonance. Invest Radiol. 1995;30:135-143.
24. Runge VM, Wells JW, Williams NM, et al. Detectability of early brain meningitis with magnetic resonance imaging. Invest Radiol. 1995;30:484-495.
25. Runge VM, Kirsch JE, Lee C. Contrast-enhanced MR angiography. J Magn Reson Imaging. 1993;3:233-239.
26. Runge VM, Wells JW, Williams NM. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease. Invest Radiol. 1995;30:123-130.
27. Runge VM, Wells JW, Williams NM. Evaluation of gadolinium 2,5-BPADO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging. Invest Radiol. 1996;31:11-16. (Pubitemid 26017731)
28. Runge VM, Wells JW, Williams NM, et al. The use of gadolinium-BOPTA on magnetic resonance imaging in brain infection. Invest Radiol. 1996;31: 294-299. (Pubitemid 26137162)
29. Runge VM, Lee C, Williams NM. Detectability of small liver metastases with gadolinium BOPTA. Invest Radiol. 1997;32:557-565. (Pubitemid 28049502)
30. Runge VM. Splitting vial of MR contrast is not good patient care. Diagn Imaging (San Franc). 1998;20:23-24.
31. Prince MR, Schoenberg SO, Ward JS, et al. Hemodynamically significant atherosclerotic renal artery stenosis: MR angiographic features. Radiology. 1997;205:128-136. (Pubitemid 27415137)
32. Runge VM, Kenney CM. Phase II double-blind, dose-ranging clinical evaluation of gadobenate dimeglumine in focal liver lesions: with analysis of liver and kidney signal change on early and delayed imaging. J Magn Reson Imaging. 2000;11:655-664. (Pubitemid 30350309)
33. Runge VM, Armstrong MR, Barr RG, et al. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol. 2001;36:65-71. (Pubitemid 32147852)
34. Biswas J, Nelson CB, Runge VM, et al. Brain tumor enhancement in magnetic resonance imaging: comparison of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) at 1.5 versus 3 tesla. Invest Radiol. 2005;40: 792-797. (Pubitemid 41690437)
35. Runge VM, Patel MC, Baumann SS, et al. T1-weighted imaging of the brain at 3 tesla using a 2-dimensional spoiled gradient echo technique. Invest Radiol. 2006;41:68-75. (Pubitemid 44406201)
36. Runge VM, Parker JR, Donovan M. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol. 2002;37:269-280. (Pubitemid 34461673)
37. Runge VM, Biswas J, Wintersperger BJ, et al. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol. 2006;41:244-248. (Pubitemid 44406184)
38. Attenberger UI, Runge VM, Jackson CB, et al. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T. Invest Radiol. 2009;44:251-256.
39. Attenberger UI, Runge VM, Morelli JN, et al. Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T. J Magn Reson Imaging. 2010;31:549-555.
40. Runge VM. Allergic reactions to gadolinium chelates. Am J Roentgenol. 2001;177:944-945.
41. Runge VM, Dickey KM, Williams NM, et al. Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media. Invest Radiol. 2002;37:393-398. (Pubitemid 34680201)
42. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
43. Port M, Idee JM, Medina C, et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21:469-490.
44. Hermann P, Kotek J, Kubícek V, et al. Gadolinium(iii) complexes as MRI contrast agents: ligand design and properties of the complexes. Dalton Transactions. 2008;30:27-47.
45. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol. 2008;66:160-167.
46. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol. 2007;42:139-145. (Pubitemid 46104895)
47. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724. (Pubitemid 41546838)
48. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41:213-221. (Pubitemid 44406181)
49. Weinmann HJ, Brasch RC, Press WR, et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol. 1984; 142:619-624. (Pubitemid 14199123)
50. Runge VM. Notes on "Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent." Am J Roentgenol. 2008;190:1433-1434. (Pubitemid 351798515)
51. Bonnemain B, Meyer D. Present aspects of MRI contrast agents-early experience with DOTA gadolinium. Presented at: "MR 85" Meeting; January 24-27, 1985; Garmisch Partenkirchen, West Germany.
52. Runge VM, Gelblum DY, Pacetti ML, et al. Gd-HP-DO3A in clinical MR imaging of the brain. Radiology. 1990;177:393-400. (Pubitemid 20374855)
53. Tweedle MF. The ProHance story: the making of a novel MRI contrast agent. Eur Radiol. 1997;7(suppl 5):225-230.
54. Greco A, McNamara MT, Lanthiez P, et al. Gadodiamide injection: nonionic gadolinium chelate for MR imaging of the brain and spine-phase II-III clinical trial. Radiology. 1990;176:451-456. (Pubitemid 20225135)
55. Runge VM, Kuehl TJ, Jackson CB, et al. Subchronic toxicity of the gadolinium chelates. Acad Radiol. 2005;12(suppl 1):S6-S9. (Pubitemid 41150885)
56. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging. 1990;8:467-481. (Pubitemid 20321961)
57. Pavone P, Patrizio G, Buoni C, et al. Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver. Radiology. 1990;176:61-64. (Pubitemid 20208107)
58. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004;230: 55-64. (Pubitemid 37549783)
59. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, et al. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med. 1991;22:233-237; discussion 242.
60. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOBDTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785-792.
61. Staks T, Schuhmann-Giampieri G, Frenzel T, et al. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol. 1994;29:709-715. (Pubitemid 24258267)
62. Adzamli K, Periasamy MP, Spiller M, et al. NMRD assessment of Gd-DTPA-bis(methoxyethylamide), (Gd-DTPA-BMEA), a nonionic MRI agent. Invest Radiol. 1999;34:410-414. (Pubitemid 29239357)
63. Rubin DL, Desser TS, Semelka R, et al. A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial. J Magn Reson Imaging. 1999;9:240-250. (Pubitemid 29115348)
64. Swan SK, Baker JF, Free R, et al. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging. 1999;9:317-321. (Pubitemid 29115359)
65. Parmelee DJ, Walovitch RC, Ouellet HS, et al. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol. 1997;32:741-747. (Pubitemid 28053505)
66. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol. 2006;41:206-212. (Pubitemid 44406180)
67. Revel D, Loubeyre P, Delignette A, et al. Contrast-enhanced magnetic resonance tomoangiography: a new imaging technique for studying thoracic great vessels. Magn Reson Imaging. 1993;11:1101-1105.
68. Belliveau JW, Rosen BR, Kantor HL, et al. Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med. 1990;14:538-546. (Pubitemid 20248637)
69. Rosen BR, Belliveau JW, Aronen HJ, et al. Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med. 1991;22: 293-299; discussion 300-293.
70. Runge VM, Kirsch JE, Wells JW, et al. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced, steady-state free-precession MR imaging: an animal study. Am J Roentgenol. 1993;160:593-600. (Pubitemid 23074869)
71. Runge VM, Wells JW. Choice of metal ion and formulation concentration for first-pass brain perfusion studies with magnetic resonance imaging at 1.5 tesla. Invest Radiol. 1996;31:395-400. (Pubitemid 26238981)
72. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol. 2006;16:2619-2621. (Pubitemid 44823915)
73. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
74. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009;44: 226-233.
75. Herborn CU, Watkins DM, Baumann S, et al. Contrast-enhanced magnetic resonance angiography: P792 blood pool agent versus Gd-DOTA in rabbits at 3.0 T versus 1.5 T. Invest Radiol. 2007;42:622-628. (Pubitemid 47262930)
76. Melancon MP, Wang Y, Wen X, et al. Development of a macromolecular dual-modality MR-optical imaging for sentinel lymph node mapping. Invest Radiol. 2007;42:569-578. (Pubitemid 47051834)
77. Peukert D, Kaufels N, Laule M, et al. Improved evaluation of myocardial perfusion and viability with the magnetic resonance blood pool contrast agent p792 in a nonreperfused porcine infarction model. Invest Radiol. 2007;42:248-255. (Pubitemid 46398864)
78. Spuentrup E, Katoh M, Buecker A, et al. Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest Radiol. 2007;42:586-595. (Pubitemid 47051836)
79. Peldschus K, Hamdorf M, Robert P, et al. Contrast-enhanced magnetic resonance angiography: evaluation of the high relaxivity low diffusible gadoliniumbased contrast agent P846 in comparison with gadoterate meglumine in rabbits at 1.5 Tesla and 3.0 Tesla. Invest Radiol. 2008;43:837-842.
80. Woods M, Caravan P, Geraldes CF, et al. The effect of the amide substituent on the biodistribution and tolerance of lanthanide(III) DOTA-tetraamide derivatives. Invest Radiol. 2008;43:861-870.
81. Alsaid H, De Souza G, Bourdillon MC, et al. Biomimetic MRI contrast agent for imaging of inflammation in atherosclerotic plaque of ApoEF/Rmice: a pilot study. Invest Radiol. 2009;44:151-158.
82. Fries P, Runge VM, Bucker A, et al. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model. Invest Radiol. 2009;44:200-206.
83. Katoh M, Haage P, Wiethoff AJ, et al. Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent: a feasibility study. Invest Radiol. 2009;44:146-150.
84. Vymazal J, Spuentrup E, Cardenas-Molina G, et al. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol. 2009;44:697-704.
85. Bazeli R, Coutard M, Duport BD, et al. In vivo evaluation of a new magnetic resonance imaging contrast agent (P947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms. Invest Radiol. 2010;45:662-668.
86. Frericks BB, Kuhl AA, Loddenkemper C, et al. Gadofluorine M-enhanced magnetic resonance imaging of inflammatory bowel disease: quantitative analysis and histologic correlation in a rat model. Invest Radiol. 2011;46: 478-485.
87. Kinner S, Maderwald S, Parohl N, et al. Contrast-enhanced magnetic resonance angiography in rabbits: evaluation of the gadolinium-based agent p846 and the iron-based blood pool agent p904 in comparison with gadoterate meglumine. Invest Radiol. 2011;46:524-529.
88. Morelli JN, Runge VM, Williams JM, et al. Evaluation of a fibrin-binding gadolinium chelate peptide tetramer in a brain glioma model. Invest Radiol. 2011;46:169-177.
89. Dohr O, Hofmeister R, Treher M, et al. Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Invest Radiol. 2007;42:830-841. (Pubitemid 350126565)
90. Elgeti T, Abdel-Aty H, Wagner M, et al. Assessment of late gadolinium enhancement in nonischemic cardiomyopathy: comparison of a fast phasesensitive inversion recovery sequence (PSIR) and a conventional segmented 2D gradient echo recall (GRE) sequence-preliminary findings. Invest Radiol. 2007;42:671-675. (Pubitemid 351325898)
91. Klessen C, Hein PA, Huppertz A, et al. First-pass whole-body magnetic resonance angiography (MRA) using the blood-pool contrast medium gadofosveset trisodium: comparison to gadopentetate dimeglumine. Invest Radiol. 2007;42:659-664. (Pubitemid 47262935)
92. Michaely HJ, Kramer H, Oesingmann N, et al. Intraindividual comparison of MR-renal perfusion imaging at 1.5 T and 3.0 T. Invest Radiol. 2007;42: 406-411. (Pubitemid 46788740)
93. Nael K, Fenchel M, Krishnam M, et al. 3.u0 Tesla high spatial resolution contrast-enhanced magnetic resonance angiography (CE-MRA) of the pulmonary circulation: initial experience with a 32-channel phased array coil using a high relaxivity contrast agent. Invest Radiol. 2007;42:392-398. (Pubitemid 46788738)
94. Planchamp C, Gex-Fabry M, Becker CD, et al. Model-based analysis of Gd-BOPTA-induced MR signal intensity changes in cirrhotic rat livers. Invest Radiol. 2007;42:513-521. (Pubitemid 46955246)
95. Schneider G, Altmeyer K, Kirchin MA, et al. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging. Invest Radiol. 2007;42:105-115. (Pubitemid 46104891)
96. Tsuda N, Okada M, Murakami T. Potential of gadolinium- ethoxybenzyldiethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol. 2007;42:242-247. (Pubitemid 46398863)
97. Wintersperger BJ, Runge VM, Biswas J, et al. Brain tumor enhancement in MR imaging at 3 Tesla: comparison of SNR and CNR gain using TSE and GRE techniques. Invest Radiol. 2007;42:558-563. (Pubitemid 47051832)
98. Asbach P, Warmuth C, Stemmer A, et al. High spatial resolution T1-weighted MR imaging of liver and biliary tract during uptake phase of a hepatocyte-specific contrast medium. Invest Radiol. 2008;43:809-815.
99. Bueltmann E, Erb G, Kirchin MA, et al. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla. Invest Radiol. 2008;43:695-702.
100. Kim JI, Lee JM, Choi JY, et al. The value of gadobenate dimeglumineenhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008;43:202-210. (Pubitemid 351643147)
101. Mewton N, Croisille P, Revel D, et al. Left ventricular postmyocardial infarction remodeling studied by combining MR-tagging with delayed MR contrast enhancement. Invest Radiol. 2008;43:219-228. (Pubitemid 351416765)
102. Michaely HJ, Attenberger UI, Dietrich O, et al. Feasibility of gadofosvesetenhanced steady-state magnetic resonance angiography of the peripheral vessels at 3 Tesla with Dixon fat saturation. Invest Radiol. 2008;43:635-641.
103. Sardanelli F, Fausto A, Esseridou A, et al. Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: effect of higher initial enhancement thresholds on diagnostic performance. Invest Radiol. 2008;43:236-242. (Pubitemid 351416767)
104. Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPAenhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43:504-511.
105. Bauner KU, Reiser MF, Huber AM. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine. Invest Radiol. 2009;44:95-104.
106. Hahn G, Sorge I, Gruhn B, et al. Pharmacokinetics and safety of gadobutrolenhanced magnetic resonance imaging in pediatric patients. Invest Radiol. 2009;44:776-783.
107. Hammerstingl R, Adam G, Ayuso JR, et al. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial. Invest Radiol. 2009;44:168-176.
108. Huppertz A, Kroll H, Klessen C, et al. Biphasic blood pool contrast agent-enhanced whole-body MR angiography for treatment planning in patients with significant arterial stenosis. Invest Radiol. 2009;44:422-432.
109. Ludemann L, Nafz B, Elsner F, et al. Absolute quantification of regional renal blood flow in swine by dynamic contrast-enhanced magnetic resonance imaging using a blood pool contrast agent. Invest Radiol. 2009;44:125-134.
110. Prompona M, Cyran C, Nikolaou K, et al. Contrast-enhanced whole-heart MR coronary angiography at 3.0 T using the intravascular contrast agent gadofosveset. Invest Radiol. 2009;44:369-374.
111. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol. 2009;44:305-310.
112. Bhat H, Yang Q, Zuehlsdorff S, et al. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3 T using interleaved echo planar imaging. Invest Radiol. 2010;45:458-464.
113. Chang JM, Moon WK, Cha JH, et al. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine. Invest Radiol. 2010;45:655-661.
114. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141.
115. Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol. 2010;45:740-746.
116. Lobbes MB, Heeneman S, Passos VL, et al. Gadofosveset-enhanced magnetic resonance imaging of human carotid atherosclerotic plaques: a proofof-concept study. Invest Radiol. 2010;45:275-281.
117. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (f2 or C2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol. 2010;45:96-103.
118. Katsube T, Okada M, Kumano S, et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol. 2011;46:277-283.
119. Motosugi U, Ichikawa T, Sano K, et al. Double-dose gadoxetic Acidenhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol. 2011;46:141-145.
120. Percy DB, Ribot EJ, Chen Y, et al. In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol. 2011;46:718-725.
121. Wagner M, Rosler R, Lembcke A, et al. Whole-heart coronary magnetic resonance angiography at 1.5 Tesla: does a blood-pool contrast agent improve diagnostic accuracy? Invest Radiol. 2011;46:152-159.
122. Wang H, Miranda Cona M, Chen F, et al. Comparison between nonspecific and necrosis-avid gadolinium contrast agents in vascular disrupting agentinduced necrosis of rodent tumors at 3.0T. Invest Radiol. 2011;46:531-538.
123. Haneder S, Attenberger UI, Biffar A, et al. Gadofosveset: parameter optimization for steady-state imaging of the thoracic and abdominal vasculature. Invest Radiol. 2011;46:678-685.
124. Cochet A, Lalande A, Walker PM, et al. Comparison of the extent of delayed-enhancement cardiac magnetic resonance imaging with and without phase-sensitive reconstruction at 3.0 T. Invest Radiol. 2007;42:372-376. (Pubitemid 46788735)
125. Kosaka N, Uematsu H, Kimura H, et al. Assessment of the vascularity of uterine leiomyomas using double-echo dynamic perfusion-weighted MRI with the first-pass pharmacokinetic model: correlation with histopathology. Invest Radiol. 2007;42:629-635. (Pubitemid 47262931)
126. Kramer H, Michaely HJ, Matschl V, et al. High-resolution magnetic resonance angiography of the lower extremities with a dedicated 36-element matrix coil at 3 Tesla. Invest Radiol. 2007;42:477-483. (Pubitemid 46788749)
127. Ruan C, Yang SH, Cusi K, et al. Contrast-enhanced first-pass myocardial perfusion magnetic resonance imaging with parallel acquisition at 3.0 Tesla. Invest Radiol. 2007;42:352-360. (Pubitemid 46788733)
128. Steen H, Lima JA, Chatterjee S, et al. High-resolution three-dimensional aortic magnetic resonance angiography and quantitative vessel wall characterization of different atherosclerotic stages in a rabbit model. Invest Radiol. 2007;42:614-621. (Pubitemid 47262929)
129. Ganguli S, Pedrosa I, Smith MP, et al. Low dose pedal magnetic resonance angiography at 3 tesla with time-resolved imaging of contrast kinetics: a feasibility study. Invest Radiol. 2008;43:650-655.
130. Welsch GH, Mamisch TC, Hughes T, et al. In vivo biochemical 7.0 Tesla magnetic resonance: preliminary results of dGEMRIC, zonal T2, and T2* mapping of articular cartilage. Invest Radiol. 2008;43:619-626.
131. Lohan DG, Tomasian A, Saleh RS, et al. Ultra-low-dose, time-resolved contrast-enhanced magnetic resonance angiography of the carotid arteries at 3.0 tesla. Invest Radiol. 2009;44:207-217.
132. Trattnig S, Burstein D, Szomolanyi P, et al. T1(Gd) gives comparable information as Delta T1 relaxation rate in dGEMRIC evaluation of cartilage repair tissue. Invest Radiol. 2009;44:598-602.
133. Bittersohl B, Hosalkar HS, Werlen S, et al. Intravenous versus intra-articular delayed gadolinium-enhanced magnetic resonance imaging in the hip joint: a comparative analysis. Invest Radiol. 2010;45:538-542.
134. Mayerhoefer ME, Welsch GH, Riegler G, et al. Feasibility of texture analysis for the assessment of biochemical changes in meniscal tissue on T1 maps calculated from delayed gadolinium-enhanced magnetic resonance imaging of cartilage data: comparison with conventional relaxation time measurements. Invest Radiol. 2010;45:543-547.
135. Jacquier A, Prost C, Amabile N, et al. Gadolinium chelate kinetics in cardiac MR imaging of myocarditis: comparison to acute myocardial infarction and impact on late gadolinium enhancement. Invest Radiol. 2011;46:705-710.
136. Bourrinet P, Martel E, El Amrani AI, et al. Cardiovascular safety of gadoterate meglumine (Gd-DOTA). Invest Radiol. 2007;42:63-77. (Pubitemid 46104886)
137. Herborn CU, Honold E, Wolf M, et al. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol. 2007;42:58-62. (Pubitemid 46072553)
138. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817-828.
139. Yrjana SK, Vaara T, Karttunen A, et al. Pulse repetition time and contrast enhancement: simulation study of Gd-BOPTA and conventional contrast agent at different field strengths. Invest Radiol. 2008;43:267-275. (Pubitemid 351416770)
140. Wintersperger BJ, Runge VM, Tweedle MF, et al. Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents. Invest Radiol. 2009;44:89-94.
141. Dumas S, Jacques V, Sun WC, et al. High relaxivity magnetic resonance imaging contrast agents. Part 1. Impact of single donor atom substitution on relaxivity of serum albumin-bound gadolinium complexes. Invest Radiol. 2010;45:600-612.
142. Jacques V, Dumas S, Sun WC, et al. High-relaxivity magnetic resonance imaging contrast agents. Part 2. Optimization of inner-and second-sphere relaxivity. Invest Radiol. 2010;45:613-624.
143. Liang J, Sammet S, Yang X, et al. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging. Invest Radiol. 2010;45:233-244.
144. Fretellier N, Idee JM, Dencausse A, et al. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol. 2011;46:292-300.
145. Gschwend S, Ebert W, Schultze-Mosgau M, et al. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol. 2011;46:556-566.
146. Lowe A, Breuer J, Palkowitsch P. Evaluation of the effect of two gadolinium-containing contrast-enhancing agents, gadobutrol and gadoxetate disodium, on colorimetric calcium determinations in serum and plasma. Invest Radiol. 2011;46:366-369.
147. Voth M, Rosenberg M, Breuer J. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance. Invest Radiol. 2011;46:663-671.
148. Noebauer-Huhmann IM, Szomolanyi P, Juras V, et al. Gadolinium-based magnetic resonance contrast agents at 7 Tesla: in vitro T1 relaxivities in human blood plasma. Invest Radiol. 2010;45:554-558.
149. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
150. Bhagavathula N, DaSilva M, Aslam MN, et al. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol. 2009;44:433-439.
151. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol. 2009;44:135-139.
152. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol. 2009;44:74-81.
153. Bhagavathula N, Dame MK, DaSilva M, et al. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol. 2010;45:769-777.
154. DaSilva M, O'Brien Deming M, Fligiel SE, et al. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol. 2010;45:733-739.
155. Haylor J, Dencausse A, Vickers M, et al. Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol. 2010;45:507-512.
156. Perone PA, Weber SL, DaSilva M, et al. Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol. 2010;45:42-48.
157. Steger-Hartmann T, Hofmeister R, Ernst R, et al. A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis. Invest Radiol. 2010;45:520-528.
158. Wiesinger B, Kehlbach R, Bebin J, et al. Effects of MRI contrast agents on human embryonic lung fibroblasts. Invest Radiol. 2010;45:513-519.
159. Fretellier N, Idee JM, Guerret S, et al. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol. 2011;46:85-93.
160. Macneil S, Bains S, Johnson C, et al. Gadolinium contrast agent associated stimulation of human fibroblast collagen production. Invest Radiol. 2011; 46:711-717.
161. Pietsch H, Raschke M, Ellinger-Ziegelbauer H, et al. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol. 2011;46:48-56.
162. Wiesinger B, Kehlbach R, Hemsen J, et al. Effects of magnetic resonance imaging contrast agents on human umbilical vein endothelial cells and evaluation of magnetic resonance imaging contrast media-triggered transforming growth factor-beta induction in dermal fibroblasts (HSF) as a model for nephrogenic systemic fibrosis. Invest Radiol. 2011;46:71-76.